Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (688)	3/15/2007 10:33:57 AM
From: zeta1961	Respond to of 802

OT: not bad for a day's work-g-

To: Jibacoa who wrote (688)	3/15/2007 10:36:35 AM
From: zeta1961	Read Replies (1) \| Respond to of 802

AACR abstracts are online..I could only find the poster presentations.. Here's one using KOSN's 17 AAG in lung cancer cells resistant to Mda7..they talk cell death 'enhancement' but no percentages given..yawn... Abstract Number: 3326 Presentation Title: Geldanamycin and its 17-Allyl-amino-17-demethoxy analogue overcome Ad-mda7 resistance in lung cancer cells Presentation Start/End Time: Monday, Apr 16, 2007, 1:00 PM - 5:00 PM Location: Exhibit Hall, Los Angeles Convention Center Poster Section: 32 Poster Board Number: 9 Author Block: Abujiang Pataer, Sunil Chada, Jack A. Roth, Kelly K. Hunt, Stephen G. Swisher. UT M.D. Anderson Cancer Ctr., Houston, TX, Introgen Therapeutics Inc, Houston, TX We analyzed Ad-mda7 resistant cell lines in an effort to understand, at a molecular level, the reasons for this resistance. Resistant A549 cell lines were generated by repeated selection of resistant clones from Ad-mda7-sensitive A549 parental cells. Two Ad-mda7-resistant cell lines are resistant to both adenoviral vectors and the mda-7 gene (designated A549R1 and A549R2) while two others (A549R3 and A549R4) are resistant only to the therapeutic mda-7 gene. Similar levels of AKT and phospho-AKT expression were noted in the parental A549 and A549R3 resistant cells. Compared with parental A549, we found slightly increased expression of bcl-2 and decreased expression of bcl-xL on A549R3 resistant cells. We have shown that combining GA or 17AAG with Ad-mda7 enhances cell death in A549 and H460 lung cancer cells. We therefore investigated whether the combinations would have similar effects on Ad-mda7-resistant cell lines. We examined the effects of Ad-mda7 combined with 50 nM GA or 17AAG for 48 h in A549R3. We found that the combination of GA or 17AAG and Ad-mda7 treatment resulted in an enhancement of cell death in A549R3 cells. Geldanamycin or 17AAG can overcome Ad-mda7 resistance in an established in vitro model.

To: Jibacoa who wrote (688)	3/29/2007 12:02:37 PM
From: zeta1961	Read Replies (1) \| Respond to of 802

Bernard, I would not be surprised if they recommend at the very least, conditional approval(unlike like approvable that the bears predict)..and if the stock wasn't halted, I'd place a bet that the outcome would be good..they have the 9902B at about 2/3 enrolled.. The FDA statisticians presented the stat theories of how DNDN wasted all alpha because their primary endpoint of TTP was not met, but indicated how because OS is the gold standard and impossible to 'fudge', that this was clinically meaningful..and none of the FDAs statistical sensitivity studies showed there was a bias leading to false good survival data.. There were more CVAs in the Provenge group but nobody on the panel made much of it since it was not signficant.. I don't see any acrimony between the panel and DNDN..this is the same committee that will listen to INGN..main reason I payed to view this one..